Amgen's director of value, access and policy, Ian Noble, says a vision and agreed principles are essential to ensuring the pending HTA review avoids becoming just another negotiation and actually delivers for Australian patients. …
Amgen's Ian Noble - 'If it doesn't get measured, it doesn't get done'
December 14, 2021 Latest NewsBioPharmaBioPharmaDispatch ExecutivePodcast
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News